The associate professor of neurology at the University of Naples provided context on the mechanism of action for dimethyl fumarate and why there’s belief it can benefit patients with Friedreich ataxia. [WATCH TIME: 4 minutes]
Fracesco Saccà, MD, PhD
Advertisement
Articles by Fracesco Saccà, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Subcutaneous Efgartigimod Shows Efficacy in Phase 2 ALKIVIA, Phase 3 ADAPT SERON Trials
2
B-Cell Modulator Obexelimab Shows Pronounced Relapse Reduction in Phase 2 MoonStone Trial
3
Open-Label Extension Highlights Continued Therapeutic Benefit of Nipocalimab in Patients Transitioning From Placebo
4
Independent Adjudication Committee Helps Facilitate Accurate Enrollment of Phase 2/3 ARISE Trial of Nipocalimab
5
